Malaysia Medical Device Classification: Four Risk Classes and No Class II

1. Key takeaways

Malaysia classifies medical devices into four risk classes: Class A for low risk, Class B for low to medium risk, Class C for medium to high risk and Class D for high risk. There is no Class II in the Malaysian system, and this is not a matter of terminology. The four classes cannot be mapped directly onto the European classes I, IIa, IIb and III, nor onto the United States classes I, II and III, because the rules that produce them are different rules with different triggers. A device that carries a particular class in another jurisdiction must be classified again under the Malaysian rules, and the earlier class is at most a starting hypothesis.

• Four classes only: A (low), B (low to medium), C (medium to high) and D (high), with no Class II tier at any point.
• Classification is governed by the First Schedule to the Medical Device Regulations 2012, in its Part II, and IVDs are classified under the separate rules in Appendix 2 to that Schedule.
• The rules turn on intended use, duration of use, and the degree and site of invasiveness, including whether the device contacts the body surface, a body orifice, is surgically invasive, or reaches the central circulatory system or the central nervous system.
• The manufacturer performs the classification, and the reasoning forms part of the registration application.
• Where the manufacturer and the CAB disagree, the MDA decides the question.
• Class drives both the conformity assessment route and the fee tier, with official fees rising from Class A through Class B and Class C to Class D.

2. Legal basis

The classification rules sit in the First Schedule to the Medical Device Regulations 2012, Part II, and are supplemented for IVDs by Appendix 2 to the same Schedule. The factors that the rules weigh are prescribed rather than discretionary: the intended purpose of the device, the duration of its use, whether that use is transient, short-term or long-term, and the degree and anatomical site of invasiveness. The list of sites is specific and includes the body surface, body orifices, surgically invasive use, the central circulatory system and the central nervous system. Because duration and site are independent variables, a device can migrate between classes when either changes, which is why a change in the instructed wearing time or in the access route is a regulatory event and not merely a labelling edit.

Responsibility for classification rests with the manufacturer, under the First Schedule and Section 3 of Act 737. The manufacturer does not merely select a class; it submits the basis for the selection as part of the registration application, so the reasoning becomes part of the record that the CAB and the MDA review. Where the manufacturer and the CAB reach different conclusions, the disagreement is resolved by the MDA rather than by negotiation between the parties.

The legal consequence of the class is twofold. It determines the conformity assessment route that the device must follow, and it determines the tier at which official fees are charged, since the fees in the Fifth Schedule rise from Class A through Class D. A misclassification is therefore not a presentational defect that can be corrected at the end of a review. It produces rejection, additional fees and, in the more serious cases, a requirement to file again, with the schedule consequences that follow from restarting an application.

3. Expert insights

The most frequent error made by Chinese manufacturers in Malaysia is the assumption that a non-sterile disposable consumable belongs in Class A by default. Where the intended use involves an invasive procedure, the First Schedule rules are likely to place the product in Class B or Class C, because invasiveness and duration are the operative criteria and sterility is not the test. A product can be non-sterile and still invasive, and it can be a simple article and still long-term. Working rule by rule, and recording the rule relied on for each product, is slower at the outset than assigning a class by analogy to another market, but it is the only method that survives review.

The second insight is that the absence of a Class II tier has consequences beyond vocabulary. Teams accustomed to European classifications often carry a two-thirds mapping in their heads, treating EU Class IIa as Malaysian Class B and EU Class IIb as Class C. The coincidence in some cases is not a rule, and the exceptions are precisely where the cost sits, because a device that is Class IIa in Europe may fall into Class C under the Malaysian invasiveness and duration criteria. The class must be derived from the First Schedule text, and the derivation should be written down in the language the schedule uses.

The third insight concerns evidence strategy. When the correct class is genuinely uncertain after a careful reading, the conservative course is to prepare the evidence at the higher of the candidate classes, because the evidentiary burden of the higher class is a superset of the lower one and the cost of upward correction mid-review is higher than the cost of preparing a fuller file at the start. This is a planning technique, not a substitute for the determination: the class submitted must still be the class the rules support, and the reasoning must be able to withstand a CAB query or an MDA ruling.

4. Practical recommendations

• Derive the class from the First Schedule text for every product, and write the derivation into the file in the schedule’s own terms, citing the rule applied.
• Record duration of use and anatomical site as explicit data fields in the technical file, since both are rule triggers and both are easy to leave implicit.
• Treat any change in instructed duration, access route or anatomical contact as a classification review trigger rather than a labelling change.
• Do not import a class from an EU or US certificate; record the foreign class as background information only, and keep it clearly separated from the Malaysian determination.
• Budget the fee at the correct tier from the outset, and treat a fee tier that looks unexpectedly low as a signal that the class may be understated.
• Where the class remains uncertain after a full reading of the rules, prepare the evidence at the higher candidate class and keep a written note of why the lower class was rejected.

5. Verification checklist

• □ First Schedule to the Medical Device Regulations 2012, Part II, read in full, including the definitions of transient, short-term and long-term use (pending verification).
• □ Appendix 2 to the First Schedule confirmed as the IVD-specific rule set where the product is an IVD (pending verification).
• □ Act 737 Section 3 confirmed as the provision assigning classification responsibility to the manufacturer (pending verification).
• □ The classification rationale in the application traced rule by rule to the schedule text (pending verification).
• □ Fee tier checked against the Fifth Schedule for the class actually claimed (pending verification).
• □ Any disagreement with the CAB on class referred to the MDA for decision rather than resolved internally (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com